Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Previously Published Works bannerUCSF

An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.

  • Author(s): Christenson, Stephanie A
  • van den Berge, Maarten
  • Faiz, Alen
  • Inkamp, Kai
  • Bhakta, Nirav
  • Bonser, Luke R
  • Zlock, Lorna T
  • Barjaktarevic, Igor Z
  • Barr, R Graham
  • Bleecker, Eugene R
  • Boucher, Richard C
  • Bowler, Russell P
  • Comellas, Alejandro P
  • Curtis, Jeffrey L
  • Han, MeiLan K
  • Hansel, Nadia N
  • Hiemstra, Pieter S
  • Kaner, Robert J
  • Krishnanm, Jerry A
  • Martinez, Fernando J
  • O'Neal, Wanda K
  • Paine, Robert
  • Timens, Wim
  • Wells, J Michael
  • Spira, Avrum
  • Erle, David J
  • Woodruff, Prescott G
  • et al.

Published Web Location

https://doi.org/10.1172/jci121087
Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a heterogeneous smoking-related disease characterized by airway obstruction and inflammation. This inflammation may persist even after smoking cessation and responds variably to corticosteroids. Personalizing treatment to biologically similar "molecular phenotypes" may improve therapeutic efficacy in COPD. IL-17A is involved in neutrophilic inflammation and corticosteroid resistance, and thus may be particularly important in a COPD molecular phenotype.

Methods

We generated a gene expression signature of IL-17A response in bronchial airway epithelial brushings from smokers with and without COPD (n = 238), and validated it using data from 2 randomized trials of IL-17 blockade in psoriasis. This IL-17 signature was related to clinical and pathologic characteristics in 2 additional human studies of COPD: (a) SPIROMICS (n = 47), which included former and current smokers with COPD, and (b) GLUCOLD (n = 79), in which COPD participants were randomized to placebo or corticosteroids.

Results

The IL-17 signature was associated with an inflammatory profile characteristic of an IL-17 response, including increased airway neutrophils and macrophages. In SPIROMICS the signature was associated with increased airway obstruction and functional small airways disease on quantitative chest CT. In GLUCOLD the signature was associated with decreased response to corticosteroids, irrespective of airway eosinophilic or type 2 inflammation.

Conclusion

These data suggest that a gene signature of IL-17 airway epithelial response distinguishes a biologically, radiographically, and clinically distinct COPD subgroup that may benefit from personalized therapy.

Trial registration

ClinicalTrials.gov NCT01969344.

Funding

Primary support from the NIH, grants K23HL123778, K12HL11999, U19AI077439, DK072517, U01HL137880, K24HL137013 and R01HL121774 and contracts HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C and HHSN268200900020C.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View